Abstract
BackgroundMitazalimab is a human FcgR crosslinking-dependent human IgG1 CD40 agonistic antibody developed for cancer immunotherapy.1–3 Mitazalimab has demonstrated a manageable safety profile when administered once every 2 weeks both with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
